RedHill Biopharma (RDHL) Profit After Tax: 2012-2023
Historic Profit After Tax for RedHill Biopharma (RDHL) over the last 11 years, with Jun 2023 value amounting to $58.9 million.
- RedHill Biopharma's Profit After Tax rose 403.13% to $58.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $11.6 million, marking a year-over-year increase of 122.61%. This contributed to the annual value of -$8.3 million for FY2024, which is 134.57% down from last year.
- According to the latest figures from Q2 2023, RedHill Biopharma's Profit After Tax is $58.9 million, which was up 844.05% from -$7.9 million recorded in Q1 2023.
- In the past 5 years, RedHill Biopharma's Profit After Tax registered a high of $58.9 million during Q2 2023, and its lowest value of -$35.7 million during Q3 2022.
- Its 3-year average for Profit After Tax is -$3.3 million, with a median of -$12.5 million in 2022.
- In the last 5 years, RedHill Biopharma's Profit After Tax slumped by 116.71% in 2019 and then skyrocketed by 403.13% in 2023.
- Quarterly analysis of 5 years shows RedHill Biopharma's Profit After Tax stood at -$11.7 million in 2019, then slumped by 108.12% to -$24.3 million in 2020, then dropped by 0.17% to -$24.4 million in 2021, then surged by 84.70% to -$3.7 million in 2022, then skyrocketed by 403.13% to $58.9 million in 2023.
- Its Profit After Tax was $58.9 million in Q2 2023, compared to -$7.9 million in Q1 2023 and -$3.7 million in Q4 2022.